Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)

NCT01489722 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01489722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01489722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
February 29, 2012
Completion date
May 31, 2014
Enrollment
55 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia